A Randomized, Double-Blind, Active Placebo-Controlled, Multicenter Efficacy and Safety Pilot Study of OKV-1001 for the Treatment of Primary (Non- Associative) Canine Immune-Mediated Hemolytic Anemia
Principal Investigator: John Loftus
Co-PI: Robert Goggs
Department of Clinical Sciences
Email:
jpl249@cornell.edu
Sponsor:
Okava Pharmaceuticals Inc
Title:
A Randomized, Double-Blind, Active Placebo-Controlled, Multicenter Efficacy and Safety Pilot Study of OKV-1001 for the Treatment of Primary (Non- Associative) Canine Immune-Mediated Hemolytic Anemia
Project Amount:
$199,942
Project Period:
November 2021
to
November 2024